Nuwellis (NASDAQ:NUWE – Get Free Report) and OPKO Health (NASDAQ:OPK – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.
Institutional and Insider Ownership
3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 20.1% of Nuwellis shares are owned by insiders. Comparatively, 49.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Nuwellis and OPKO Health”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuwellis | $8.27 million | 0.31 | -$17.52 million | ($90.92) | -0.01 |
| OPKO Health | $606.90 million | 1.41 | -$225.68 million | ($0.30) | -3.77 |
Nuwellis has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nuwellis and OPKO Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuwellis | -211.86% | -6,094.26% | -231.24% |
| OPKO Health | -37.19% | -17.42% | -11.24% |
Analyst Ratings
This is a summary of recent ratings for Nuwellis and OPKO Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuwellis | 1 | 0 | 1 | 0 | 2.00 |
| OPKO Health | 1 | 3 | 2 | 1 | 2.43 |
OPKO Health has a consensus price target of $2.03, indicating a potential upside of 79.94%. Given OPKO Health’s stronger consensus rating and higher possible upside, analysts clearly believe OPKO Health is more favorable than Nuwellis.
Risk & Volatility
Nuwellis has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Summary
OPKO Health beats Nuwellis on 13 of the 15 factors compared between the two stocks.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
